Most TSC caregivers plan to continue Epidiolex due to benefits like fewer seizures and improved cognition. New data at AES 2024 underscores Epidiolex's positive impact on TSC patients' health and well ...

The Company plans to discontinue further clinical development of ganaxolone in TSC. Marinus Pharmaceuticals announced that its phase 3 trial of ganaxolone did not meet the primary end point for the ...

Please provide your email address to receive an email when new articles are posted on . Survey responses reflected positive language and communication outcomes after cannabidiol use. Further ...

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced ...

Add Yahoo as a preferred source to see more of our stories on Google. AUGUSTA, Ga. (WJBF) – A clinic at the Georgia Cancer Center that focuses on a rare condition is getting a special designation in ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved topical Hyftor for the treatment of facial angiofibroma in patients who have tuberous sclerosis ...

A phase II study to evaluate the safety, pharmacodynamics and efficacy of entinostat in combination with nivolumab plus ipilimumab in patients with renal cell carcinoma previously treated with ...

Tuberous sclerosis (TS) is a complex genetic disease that can affect many organs in the body. Many of the complications of tuberous sclerosis can be treated but it is essential to identify them early.

NICE has issued final guidance recommending the use of cannabidiol for the treatment of the rare, seizure-causing genetic disorder tuberous sclerosis complex (TSC). Around 1 in every 6000 people have ...

Part 1 results from NOVA-II, a randomized, double-blind, vehicle-controlled phase II study evaluating the safety and efficacy of OQL011 on VEGFR inhibitor associated hand-foot skin reaction in cancer ...